GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Interest Coverage

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Tonix Pharmaceuticals Holding's Operating Income for the three months ended in Dec. 2023 was $-27.33 Mil. Tonix Pharmaceuticals Holding's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Tonix Pharmaceuticals Holding Corp has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Tonix Pharmaceuticals Holding's Interest Coverage or its related term are showing as below:


TNXP's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 125.655
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Tonix Pharmaceuticals Holding Interest Coverage Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tonix Pharmaceuticals Holding Interest Coverage Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Tonix Pharmaceuticals Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Tonix Pharmaceuticals Holding's Interest Coverage

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Interest Coverage falls into.



Tonix Pharmaceuticals Holding Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tonix Pharmaceuticals Holding's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Tonix Pharmaceuticals Holding's Interest Expense was $0.00 Mil. Its Operating Income was $-118.38 Mil. And its Long-Term Debt & Capital Lease Obligation was $7.19 Mil.

GuruFocus does not calculate Tonix Pharmaceuticals Holding's interest coverage with the available data.

Tonix Pharmaceuticals Holding's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Tonix Pharmaceuticals Holding's Interest Expense was $0.00 Mil. Its Operating Income was $-27.33 Mil. And its Long-Term Debt & Capital Lease Obligation was $7.19 Mil.

GuruFocus does not calculate Tonix Pharmaceuticals Holding's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Tonix Pharmaceuticals Holding  (NAS:TNXP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Tonix Pharmaceuticals Holding Interest Coverage Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Traded in Other Exchanges
N/A
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.
Executives
Richard Newcomb Stillwell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman director, 10 percent owner, officer: Chief Executive Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan officer: Chief Medical Officer C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange director
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris officer: Chief Administrative Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes director 74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Headlines

From GuruFocus